ALVO Q4 2025 Earnings Call Summary

Q4 2025 Results:
- Total revenues: $173 million, up 13% year-over-year.
- Licensing revenues constituted 75% of total revenues, driving a gross margin of 66%.
- Adjusted EBITDA: $69 million, representing a 40% margin.
- Product revenues: $43 million, with a negative product margin of 37 due to facility upgrades and timing of orders.
- Operating cash flow: Negative $28 million, impacted by lower product revenues and inventory build-up.
Full Year 2025 Results:
- Total revenues: $593 million, up 21% year-over-year.
- Adjusted EBITDA: $137 million, a 23% margin.
- Positive operating cash flow for the first time: $7 million.
- Year-end cash balance: $172 million, bolstered by financing activities.

Alvotech is advancing its position in the biosimilars market with 30 products in development, representing over $185 million in potential global sales.
The company is addressing FDA regulatory observations from a July 2025 inspection of its Reykjavik facility, implementing a quality improvement program, and plans to resubmit applications in Q2 2026.
New manufacturing initiatives include dual sourcing for key products to enhance operational flexibility and resilience.
Successful launches in 2025 included biosimilars for Humira (AVT02) and Stelara (AVT04), with ongoing expansion in Europe and Japan.
The company raised approximately $300 million in capital to support its development programs and manufacturing capabilities.

2026 revenue guidance: $650 million to $700 million, indicating continued double-digit growth.
Adjusted EBITDA expected to rise to $180 million to $220 million, driven by portfolio expansion and increased operating scale.
The lower end of the revenue guidance does not include potential U.S. product launches, while the upper end assumes successful launches and strong commercial momentum.

The company faced complete response letters (CRLs) from the FDA for four biologics license applications, linked to the inspection findings, which could delay approvals.
Product sales have been softer, particularly in the second half of 2025, raising concerns about the sustainability of growth in the Humira biosimilar market.
Competitive pressures are intensifying, particularly with the evolving dynamics of pharmacy benefit managers (PBMs) and market share erosion from branded products.
The company’s product margin has been negative due to facility upgrades, impacting short-term profitability.

Management expressed confidence in the remediation efforts and the potential for FDA approval, emphasizing a comprehensive response to the FDA's observations.
The guidance for 2026 reflects momentum from existing product launches rather than new U.S. approvals, indicating a cautious approach to forecasting.
The dual sourcing initiative for manufacturing is seen as a critical step to enhance supply resilience and support future launches.
Concerns were raised regarding competitive pressures, with management acknowledging the need for strategic positioning and first-mover advantages in the biosimilars market.
The company remains focused on operational excellence and compliance as key priorities moving forward.

ALVO — Alvotech